Heart attacks and heart failure remain significant complications for people with diabetes, contributing to a growing health crisis. Researchers at Monash University have uncovered a promising new therapy targeting inflammation, a key driver of heart damage in diabetes patients.
A preclinical study published in the journal Cardiovascular Diabetology highlights the potential of lipoxin A4 (LXA4), a natural fat molecule, to reduce inflammation and improve heart function.
